Bladder Cancer

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Daniel P. Petrylak, MD, professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.

Daniel P. Petrylak, MD, discusses the KEYNOTE-045 study results and the next steps with pembrolizumab in urothelial carcinoma.

Immunotherapy agents have been rapidly absorbed into the treatment paradigm for various cancer types. Nowhere is this more obvious than in the treatment for patients with bladder cancer. In May alone, 3 checkpoint inhibitors were approved for use in bladder cancer, bringing the total of checkpoint inhibitors approved in this field to 5 agents.

A study presented at the 2017 American Urological Association Annual Meeting demonstrated that a split-dose of gemcitabine and cisplatin as a neoadjuvant chemotherapy regimen for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.

Christophe Massard, MD, PhD, discusses ongoing clinical trials evaluating durvalumab, toxicities to be aware of with the agent, and the impact the approval has had in the field.

Findings from a recent pilot study done at the University of Pittsburgh Medical Center showed a potential link between e-cigarette use and bladder cancer.

Phillip Abbosh, MD, PhD, assistant professor, Fox Chase Cancer Center, discusses immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy.

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

When epacadostat, an IDO1 inhibitor, was combined with pembrolizumab (Keytruda), a PD-1 inhibitor, responses were seen in 35% of patients with advanced urothelial carcinoma, according to findings presented during the 2017 ASCO Annual Meeting.  

It’s been a busy month at the FDA. Here’s a look back at all the news in the oncology field to come out of the FDA during the month of May.

The addition of ramucirumab to docetaxel led to a statistically significant improvement in progression-free survival versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma.

Edward Messing, MD, discusses his paper which found patients who underwent chemotherapy following transurethral resection of bladder tumor were less likely to have tumor recurrence.

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Peter Black, MD, discusses the recent explosion of FDA approvals in the field of urothelial carcinoma, including durvalumab.

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Pembrolizumab (Keytruda) has been approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Based on results from Maslach Burnout Inventory (MBI) questions included as part of the 2016 American Urological Association (AUA) Census, burnout rates among urologists are lower than previously reported, but the issue still remains important.

Pam Profusek, RN, MS, discusses how to manage the AEs associated with immunotherapy agents, like durvalumab.

Atezolizumab failed to meet the primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.

An accelerated approval for the PD-L1 inhibitor avelumab (Bavencio) has been granted by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.